Investor Connect – Shawn Singh of VistaGen Therapeutics, Inc.

Investor Connect – Shawn Singh of VistaGen Therapeutics, Inc.

September 17, 2020 by investor

In this episode, Hall welcomes Shawn Singh, Chief Executive Officer & Director at VistaGen Therapeutics, Inc.

Located in South San Francisco, California, known as the “Birthplace of Biotech”, VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new-generation medications for anxiety, depression, and other central nervous system, or “CNS,” diseases and disorders where current treatments are inadequate to address high, unmet needs. Their CNS portfolio includes three differentiated CNS drug candidates, PH94B, PH10, and AV-101, each with a novel mechanism of action, an exceptional safety profile, and therapeutic potential for multiple indications. 

Shawn has over 25 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining VistaGen, he served as President of Artemis Neuroscience, and prior to VistaGen’s acquisition of that company, was Managing Principal of Cato BioVentures, a healthcare-focused venture capital firm.  

Earlier, Shawn assisted with the IPO of SciClone Pharmaceuticals, a revenue-generating, China-focused specialty pharmaceutical company, and served as its Chief Business Officer before departing to form Cato BioVentures with the founders of Cato Research. He began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, with a transaction-focused practice involving both emerging biotechnology and high technology companies. Shawn earned a B.A. degree, with honors, from the University of California, Berkeley, and a J.D. degree from the University of Maryland School of Law. He is a member of the State Bar of California.

Shawn explains this domain in great detail and the work he and his team do, which is focusing on medications that address both neuropsychiatric and neurological disorders. He describes the current standard of care in this industry and how it can be improved. Shawn also shares with Hall a benefit of the COVID-19 pandemic, in that it has helped lessen the stigma attached to mental health illnesses.

You can visit VistaGen Therapeutics at www.vistagen.com/, or via their LinkedIn page at www.linkedin.com/company/vistagen-therapeutics, or on Twitter at https://twitter.com/vistagen.  

Shawn can be contacted via LinkedIn at https://in/shawnsingh/, and via email at ir@vistagen.com or ssingh@vistagen.com.


____________________________________________________

Copyright (c) 2020, Hall Martin and investorconnect.org. All rights reserved.

Disclaimer:
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.

Tags: